Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does RITUXIMAB Cause Focal segmental glomerulosclerosis? 73 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 73 reports of Focal segmental glomerulosclerosis have been filed in association with RITUXIMAB (Rituxan). This represents 0.0% of all adverse event reports for RITUXIMAB.

73
Reports of Focal segmental glomerulosclerosis with RITUXIMAB
0.0%
of all RITUXIMAB reports
4
Deaths
26
Hospitalizations

How Dangerous Is Focal segmental glomerulosclerosis From RITUXIMAB?

Of the 73 reports, 4 (5.5%) resulted in death, 26 (35.6%) required hospitalization, and 1 (1.4%) were considered life-threatening.

Is Focal segmental glomerulosclerosis Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for RITUXIMAB. However, 73 reports have been filed with the FAERS database.

What Other Side Effects Does RITUXIMAB Cause?

Off label use (39,751) Drug ineffective (32,186) Rheumatoid arthritis (19,850) Pain (16,675) Fatigue (15,602) Arthralgia (12,529) Rash (12,102) Drug intolerance (11,876) Infusion related reaction (11,871) Joint swelling (11,170)

What Other Drugs Cause Focal segmental glomerulosclerosis?

TACROLIMUS (339) MYCOPHENOLATE MOFETIL (181) PREDNISONE (173) CYCLOSPORINE (96) METHYLPREDNISOLONE (81) PREDNISOLONE (73) BASILIXIMAB (67) OMEPRAZOLE (60) LANSOPRAZOLE (55) MYCOPHENOLIC ACID (55)

Which RITUXIMAB Alternatives Have Lower Focal segmental glomerulosclerosis Risk?

RITUXIMAB vs RITUXIMAB-ABBS RITUXIMAB vs RITUXIMAB-ARRX RITUXIMAB vs RITUXIMAB-PVVR RITUXIMAB vs RIVAROXABAN RITUXIMAB vs RIVASTIGMINE

Related Pages

RITUXIMAB Full Profile All Focal segmental glomerulosclerosis Reports All Drugs Causing Focal segmental glomerulosclerosis RITUXIMAB Demographics